Adavivint
- Product NameAdavivint
- CAS1467093-03-3
- CBNumberCB23137556
- MFC29H24FN7O
- MW505.55
- MDL NumberMFCD30489411
- MOL File1467093-03-3.mol
Chemical Properties
| Density | 1.365±0.06 g/cm3(Predicted) |
| storage temp. | 2-8°C |
| solubility | DMSO:27.5(Max Conc. mg/mL);54.4(Max Conc. mM) |
| pka | 7.75±0.40(Predicted) |
| FDA UNII | 42EK42WHI5 |
Adavivint Price
| Product number | Packaging | Price | Product description | Buy |
|---|---|---|---|---|
| ChemScene CS-0031495 | 5mg | $100 | Adavivint 99.12% |
Buy |
| ChemScene CS-0031495 | 10mg | $150 | Adavivint 99.12% |
Buy |
| ChemScene CS-0031495 | 25mg | $250 | Adavivint 99.12% |
Buy |
| ChemScene CS-0031495 | 100mg | $750 | Adavivint 99.12% |
Buy |
| ChemScene CS-0031495 | 50mg | $450 | Adavivint 99.12% |
Buy |
Adavivint Chemical Properties,Usage,Production
Uses
Adavivint is an intra-articular potential disease-modifying osteoarthritis drug.Biological Activity
Adavivint (SM04690) is a potent canonical Wnt signaling pathway inhibitor with EC50 of 19.5 nM for TCF/LEF reporter gene. It was more potent than other known Wnt inhibitors in multiple cellular experiments.in vitro
Treatment of bone marrow-derived human mesenchymal stem cells (CD29+, CD44+ CD166+ CD105+ CD45-) with SM04690 induced a concentration-dependent decrease in Wnt pathway gene expression (ASCL1, LEF1, TCF7L2, TCF7 , C-262 MYC and AXIN2). Selective activation of Wnt signaling pathway with Wnt3a or GSK3β inhibitor CHIR-99021, in IEC6 (intestinal stem cells sensitive to Wnt activation), M04690 can inhibit the expression of AXIN2 and LGR5; in hMSCs, inhibit the expression of AXIN2, TCF7 and LEF1 Express. It has minimal effects on non-canonical Wnt signaling and BMP signaling. In vitro, SM04690 protects chondrocytes from metabolic breakdown.
in vivo
Intra-articular injection of Adavivint promotes cartilage growth and improves joint health in a rat model of knee osteoarthritis. In vivo, it reduces cartilage breakdown.
target